Show simple item record

dc.contributor.advisorJamiruddin, Mohd. Raeed
dc.contributor.authorShawn, Ibna Hasan
dc.date.accessioned2024-08-28T08:37:21Z
dc.date.available2024-08-28T08:37:21Z
dc.date.copyright©2023
dc.date.issued2023-11
dc.identifier.otherID 18346086
dc.identifier.urihttp://hdl.handle.net/10361/23931
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.en_US
dc.descriptionCataloged from the PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 30-31).
dc.description.abstractRenal cell carcinoma (RCC) is the predominant form of kidney cancer. It is a highly prevalent form of solid tumor, and the limited availability of accurate disease models has impeded progress in the field of human kidney cancer research and treatment. Recent pharmaceutical advances, such as immune checkpoint inhibitors and targeted treatments, have shown promising results for metastatic RCC. Collaborative clinical trials will play a vital role in effectively incorporating these regimens into clinical practice. This systematic review and meta-analysis aim to assessing the efficacy and safety of nivolumab-ipilimumab, pembrolizumab-axitinib and pazopanib in treatment of renal cell carcinoma. The clinical outcome indicators that will be evaluated include overall survival, progression-free survival, hazard ratio, overall adverse events, and severe adverse events. The objective of this research is to identify therapeutic interventions that have the potential to improve the long-term management of renal cell carcinoma (RCC) on a worldwide scale.en_US
dc.description.statementofresponsibilityIbna Hasan Shawn
dc.format.extent45 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectRCCen_US
dc.subjectDemographic analysisen_US
dc.subjectPazopaniben_US
dc.subjectNivolumab plus Ipilimumaben_US
dc.subjectProgression-free survivalen_US
dc.subjectSerious adverse eventsen_US
dc.subjectOverall adverse eventsen_US
dc.subject.lcshKidneys--Cancer--Molecular aspects.
dc.subject.lcshRenal cell carcinoma.
dc.titleAssessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysisen_US
dc.typeThesisen_US
dc.contributor.departmentSchool of Pharmacy, Brac University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record